Drug firm Abbott on Tuesday said it has tied up with various health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care.
The company said it has also joined hands with Health, Healthifyme and Fitterfly under the initiative.
Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which approximately 6.5 million users can access through PharmEasy and 1MG, the drug firm said in a statement.
The drug firm endeavours to enable personalised lifestyle and therapy interventions, so people with diabetes can achieve holistic glucose management goals, it added.
"Continued research and strategic partnerships have simplified and strengthened diabetes management over the years. New diabetes technology has paved the way for precise and informed decision making," Kalyan Sattaru, General Manager of the diabetes care business at Abbott, stated.
BeatO Co-founder and CEO Gautam Chopra noted that leveraging Abbott's FreeStyle Libre with BeatO's app ecosystem will give its users precise data, along with actionable insights to effectively manage and control blood glucose levels.
"We are continuously striving to make diabetes management more effective and convenient for our members and this programme is a step in the same direction, he added.
Similarly, Sugar.fit Co-founder and CEO Madan Somasundaram stated that the company's mission is to empower people with chronic conditions to live better and healthier lives and reverse chronic metabolic disorders.
Technology is combined with science and human coaching to help millions of Indians manage and reverse diabetes through a highly consumer-centric data-driven digital health experience, he added.
India has the second-highest diabetes population in the world.
Recent studies show that healthcare for non-communicable diseases has been interrupted in India, with up to 87 per cent of people with diabetes reducing visits to their doctor due to the pandemic, and less than half possessing a blood glucose measuring device at home.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU